Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Switching to a 2-Drug Single-Tablet Regimen

Listen as William R. Short, MD, MPH, AAHIVS, discusses the data to help you determine when switching to 2-drug single-tablet regimens may be warranted.
William R. Short, MD, MPH, AAHIVS
Released: November 10, 2021

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.

Listen as he gives his perspectives on:

  • Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TC
  • The SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patients
  • Real-world experience with switching to DTG/RPV from the OPERA study
  • The TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimen
  • The SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimen

Information on this Educational Activity

Faculty

William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS, has disclosed that he has received fees for non-CME/CE services from Janssen and consulting fees from ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Slides from CCO: Discussion of the implications and considerations of polypharmacy and cardiovascular risk on choice of ART in older PWH

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: November 29, 2021

One patient’s journey from HIV diagnosis to undetectable while trying to lose weight, from Clinical Care Options (CCO)

person default Anonymous Patient Released: November 29, 2021

Perspective on ART modification to reduce CVD risk in PWH, from Dr Jens D. Lundgren and Clinical Care Options (CCO)

Jens D. Lundgren, MD, DMSc Released: November 29, 2021

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for patients with virologic failure and resistance

W. David Hardy, MD Josep M. Llibre, MD, PhD Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue